Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0866 • ACR Convergence 2021
Characteristics Associated with Poor COVID-19 Outcomes in People with Systemic Lupus Erythematosus (SLE): Data from the COVID-19 Global Rheumatology Alliance (GRA)
Manuel Ugarte-Gil¹, Graciela Alarcn², Andrea Seet³, Zara Izadi³, Ali Duarte-Garcia⁴, Cristina Reategui-Sokolova⁵, Ann Clarke⁶, Leanna Wise⁷, Guillermo Pons-Estel⁸, Maria José Santos⁹, Sasha Bernatsky¹⁰, Sandra Lúcia Ribeiro¹¹, Samar Al Emadi¹², Jeffrey Sparks¹³, Tiffany Hsu¹⁴, Kristin D'Silva¹⁵, Naomi Patel¹⁵, Emily Gilbert¹⁶, Maria Valenzuela-Almada¹⁷, Andreas Jnsen¹⁸, Gianpiero Landolfi¹⁹, Micaela Fredi²⁰, Tiphaine Goulenok²¹, Mathilde Devaux²², Xavier Mariette²³, Viviane Queyrel²⁴, Vasco C Romão²⁵, Graça Sequeira²⁶, Rebecca Hasseli²⁷, Bimba Franziska Hoyer²⁸, Reinhard Voll²⁹, Christof Specker³⁰, Roberto Baez³¹, Vanessa Castro Coello³², Edgard Neto³³, Gilda Ferreira³⁴, Odirlei Andre Monticielo³⁵, Emily Sirotich³⁶, Jean Liew³⁷, Jonathan Hausmann³⁸, Paul Sufka³⁹, Rebecca Grainger⁴⁰, Suleman Bhana⁴¹, Wendy Costello⁴², Zachary Wallace⁴³, Lindsay Jacobsohn⁴⁴, Anja Strangfeld⁴⁵, Elsa Frazão Mateus⁴⁶, Kimme Hyrich⁴⁷, Laure Gossec⁴⁸, Loreto Carmona¹, Saskia Lawson-Tovey⁴⁷, Lianne Kearsley-Fleet⁴⁹, Martin Schaefer⁵⁰, Pedro Machado⁵¹, Philip Robinson⁵², Milena Gianfrancesco³ and Jinoos Yazdany³, ¹Hospital Guillermo Almenara Irigoyen, Essalud/Universidad Científica del Sur, Lima, Peru, ²University of Alabama at Birmingham, Birmingham, AL, ³University of California San Francisco, San Francisco, CA, ⁴Mayo Clinic, Rochester, MN, ⁵Hospital Guillermo Almenara Irigoyen, Lima, Peru, ⁶University of Calgary, Calgary, AB, Canada, ⁷LAC+USC/Keck Medicine of USC, Pasadena, CA, ⁸Centro Regional de Enfermedades Autoinmunes y Reumaticas (CREAR), Rosario, Argentina, ⁹Rheumatology Department, Hospital Garcia de Orta, Almada, Portugal, ¹⁰McGill University, Montréal, QC, Canada, ¹¹Universidade Federal do Amazonas, Amazonas, Brazil, ¹²Hamad medical corporation, Doha, Qatar, ¹³Brigham and Women's Hospital, Boston, MA, ¹⁴Brigham and Women's Hospital, Jamaica Plain, MA, ¹⁵Massachusetts General Hospital, Boston, MA, ¹⁶Mayo Clinic, Jacksonville, FL, ¹⁷Division of Rheumatology, Mayo Clinic, Rochester, MN, ¹⁸Lund University, Lund, Sweden, ¹⁹Epidemiology Research Unit, Italian Society for Rheumatology, Milan, Italy, ²⁰Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, ²¹Internal Medicine Department, Bichat Claude Bernard Hospital, Paris, France, ²²Service de Médecine Interne, CHI Poissy Saint Germain, Poissy, France, ²³Université Paris- Saclay, Rheumatology, Paris, France, ²⁴University Hospital of Nice, Nice, France, ²⁵Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Centre and European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ERN-ReCONNET); Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal, ²⁶Centro Hospitalar Universitário do Algarve, Unidade de Faro, Faro, Portugal, ²⁷Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus Liebig University Giessen, Bad Nauheim, Germany., Bad Nauheim, Germany, ²⁸Universittsklinikum Schleswig-Holstein, Kiel, Germany, ²⁹Department of Rheumatology and Clinical Immunology, University Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany, ³⁰Evangelisches Krankenhaus, Kliniken Essen-Mitte, Essen, Germany, ³¹Hospital Francisco Lopez Lima, General Roca, Rio Negro, Argentina, ³²Sanatorio Güemes, Buenos Aires, Argentina, ³³UNIFESP, São Paulo, Brazil, ³⁴Federal University of Minas Gerais, Belo Horizonte, Brazil, ³⁵Serviço de Reumatologia do Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ³⁶McMaster University, Hamilton, ON, Canada, ³⁷Boston University, Boston, MA, ³⁸Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, ³⁹HealthPartners, Eagan, MN, ⁴⁰University of Otago, Wellington, New Zealand, ⁴¹Crystal Run Health, Montvale, NJ, ⁴²Irish Children's Arthritis Network, Bansha, Ireland, ⁴³Massachusetts General Hospital, Newton, MA, ⁴⁴University of California San Francisco, Antioch, CA, ⁴⁵Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ⁴⁶Liga Portuguesa Contra as Doenças Reumáticas (LPCDR), Lisbon, Portugal, ⁴⁷University of Manchester, Manchester, United Kingdom, ⁴⁸Sorbonne Université; APHP, Rheumatology Department, Pitié-Salpêtrière Hospital, Paris, France, ⁴⁹Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ⁵⁰German Rheumatism Research Center, Berlin, Germany, ⁵¹Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ⁵²Faculty of Medicine, The University of Queensland, Herston, Australia
Background/Purpose: Preliminary data in people with SLE suggested that disease activity as well as SLE treatment at time of COVID-19 acquisition impact COVID-19 outcomes over…
Abstract Number: 0882 • ACR Convergence 2021
COVID-19 Impact Among Patients with Systemic Lupus Erythematosus
Jose Rubio¹, Suzanne krishfield¹ and Vasileios Kyttaris², ¹Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA, ²BIDMC, Boston, MA
Background/Purpose: Initial studies of SLE patients with COVID-19 revealed an increased risk for severe disease in people with distinct demographic features such as advanced age…
Abstract Number: 0970 • ACR Convergence 2021
Hippo Signaling Is a Novel Regulator of Apoptosis and Photosensitivity in Lupus Keratinocytes
Grace Hile¹, Patrick Coit², Bin Xu¹, Shannon Estadt¹, Jacob Martens³, Rachael Wasikowski¹, Lam Tsoi¹, Ramiro Iglesias-Bartolome⁴, Celine Berthier¹, Allison Billi⁵, Johann Gudjonsson⁵, Amr Sawalha² and J. Michelle Kahlenberg¹, ¹University of Michigan, Ann Arbor, MI, ²University of Pittsburgh, Pittsburgh, PA, ³Graduate Program in Immunology, University of Michigan, Ann Arbor, MI, USA, Ann Arbor, MI, ⁴NIH, National Cancer Institute, Bethesda, MD, ⁵Department of Dermatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Skin inflammation and photosensitivity are common manifestations of cutaneous (CLE) and systemic lupus erythematosus (SLE), yet the mechanisms underlying heightened cell death and epidermal…
Abstract Number: 1056 • ACR Convergence 2021
Characterization of the Patterns of Care, Access and Direct Costs of Systemic Lupus Erythematosus in Brazil: Findings from the Macunaíma Study
Mirhelen Mendes de Abreu¹, Vander Fernandes², Odirlei Andre Monticielo³, Alexandre Cristovão Maiorano¹, Fernando dos Santos Beserra¹, Flavia Rachel Moreira Lamarão⁴, Nathalie David⁴, Bruna de Veras⁴, Magda Araujo⁴, Blanca Elena Rios Gomes Bica⁵, Dalianna Luise Andrade Souto Rodrigues², Guilherme Andrade Bulbol⁶, Natalia Jardim Martins da Silva⁷, Domingos Sávio Nunes de Lima⁶ and Marta Maria das Chagas Medeiros⁷, ¹Faculdade de Medicina, Universidade Federal do Rio de Janeiro; MAPEAR Laboratory, Universidade Federal do Rio de Janeiro, Rio De Janeiro, Brazil, ²Universidade de Cuiabá, Cuiabá, Brazil, ³Serviço de Reumatologia do Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ⁴GlaxoSmithKline, Medical Department, Rio de Janeiro, Brazil, ⁵Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, ⁶Hospital Universitário Getúlio Vargas, Universidade Federal do Amazonas, Manaus, Brazil, ⁷Faculdade de Medicina, Universidade Federal do Ceará, Fortaleza, Brazil
Background/Purpose: This study evaluated the patterns of care, access and direct costs related to the management and treatment of patients with systemic lupus erythematosus (SLE)…
Abstract Number: 1263 • ACR Convergence 2021
Treatment of Pediatric Lupus Is Associated with Significant Re-Organization of B Cell Chromatin
Joyce Hui-Yuen¹, Kaiyu Jiang², Susan Malkiel³, Betty Diamond³ and James Jarvis⁴, ¹North Shore LIJ Health System, Great Neck, NY, ²University at Buffalo, Buffalo, NY, ³Northwell Health, Manhasset, NY, ⁴University at Buffalo Jacobs School of Medicine, Buffalo, NY
Background/Purpose: Systemic lupus erythematosus (SLE) may be triggered by gene-environment interactions. Data remain scarce on how epigenetic variance contributes to disease risk in pediatric SLE…
Abstract Number: 1279 • ACR Convergence 2021
Impact of Active Lupus Nephritis in Patient-Reported Outcomes from a Latin American, Multicenter Lupus Cohort
Romina Nieto¹, Eduardo Ferreira Borba², Eugenia Settecasse³, Diana Fernandez-Avila⁴, Laura Maurelli⁵, Carla Gobbi⁶, Verónica Saurit⁷, Fernando Arizpe⁸, Julieta Daniele⁹, Maria Constanza Bertolaccini¹⁰, Eduardo Kerzberg¹¹, María de los Ángeles Gargiulo¹², Anabella Rodriguez¹³, Ana Carolina Londe¹⁴, Vitalina Sousa Barbosa¹⁵, Andrese Aline Gasparin¹⁶, Carolina Albanez A Cunha Andrade¹⁷, Luciana Parente Costa Seguro¹⁸, Lucas Victoria de Oliveira Martins¹⁹, Oscar Neira²⁰, Carolina Llanos²¹, Loreto Massardo²², Antonio Iglesias²³, Ivana Nieto Aristizábal²⁴, Gloria Vasquez²⁵, Paul Mendez-Patarroyo²⁶, Lizeth de la Hoz Rueda²³, José Martínez Pérez²⁷, Reyna Sánchez Briones²⁸, Mario Pérez Cristóbal²⁹, Eduardo Martin-Nares³⁰, Yaneli Juárez-Vicuña³¹, Yelitza Gonzalez Bello³², Jorge González García³³, Dionicio Galarza-Delgado³⁴, Marcos Vázquez³⁵, Patricia Langjarh³⁵, Magaly Alva Linares³⁶, Cristina Reategui-Sokolova³⁷, Armando Calvo Quirós³⁸, Edral Rodriguez³⁹, Ricardo Robaina⁴⁰, Martín Rebella⁴¹, Graciela Alarcn⁴², Ashley Orillion⁴³, Chetan Karyekar⁴⁴, Federico Zazzetti⁴⁵ and Guillermo Pons-Estel⁴⁶, ¹Hospital Provincial de Rosario, Rosario, Argentina, ²Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, ³Instituto de Investigaciones Teóricas y Aplicadas. Facultad de Ciencias Económicas y Estadistica. Universidad Nacional de Rosario, Rosario, Argentina, ⁴Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁵Hospital Italiano de Córdoba, Córdoba, Argentina, ⁶Hospital Córdoba, Córdoba, Argentina, ⁷Hospital Privado Universitario de Córdoba, Córdoba, ⁸Hospital HIGA San Martín, La Plata, Argentina, ⁹Sanatorio Británico, Rosario, Argentina, ¹⁰Hospital Padilla, San Miguel de Tucumán, Argentina, ¹¹Hospital General de Agudos J.M. Ramos Mejía, Buenos Aires, Argentina, ¹²Instituto de Investigaciones Médicas Alfredo Lanari, Buenos Aires, Argentina, ¹³CEMIC, Buenos Aires, Argentina, ¹⁴Universidade Estadual de Campinas, Faculdade de Ciencias Médicas, São Paulo, Brazil, ¹⁵Hospital das Clinicas, Univerisad Federal de Goias, Goias, Brazil, ¹⁶Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, ¹⁷Universidad Federal de Pernambuco, Recife, Brazil, ¹⁸Hospital Das Clinicas da Faculdade de Medicina da USP, São Paulo, Brazil, ¹⁹Universidad Federal São Paulo, São Paulo, Brazil, ²⁰Hospital del Salvador, Santiago, Chile, ²¹Facultad de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile, ²²Universidad San Sebastián, Santiago, Chile, ²³Clínica de la Costa Ltda., Barranquilla, Colombia, ²⁴Fundación Valle del Lili, Cali, Colombia, ²⁵Division of rheumatology, Universidad de Antioquia, Medellin, Colombia, ²⁶Reumavance Group, Rheumatology section, Department of Internal Medicine, Fundación Santa Fe de Bogotá University Hospital; Department of Internal Medicine, School of Medicine, Universidad de Los Andes, Bogota, Colombia, ²⁷Hospital Luis Vernaza, Guayaquil, Ecuador, ²⁸Centro Médico La Raza, Ciudad de México, Mexico, ²⁹Centro Médico Nacional Siglo XXI, Ciudad de México, Mexico, ³⁰Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³¹Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, Mexico, ³²Centro de Estudios de investigación Básica y Clínica S.C, Guadalajara, Mexico, ³³Hospital Central Dr. Ignacio Morones Prieto, San Luís Potosí, Mexico, ³⁴Hospital Universitario "Dr Jose E. Gonzalez", Monterrey, Mexico, ³⁵Hospital de Clínicas I, Asunción, Paraguay, ³⁶Hospital Nacional Edgardo Rebagliatti Martins, Lima, Peru, ³⁷Hospital Guillermo Almenara Irigoyen, Lima, Peru, ³⁸Hospital Cayetano Heredia, Lima, Peru, ³⁹Hospital Docente Padre Billini, Santo Domingo, Dominican Republic, ⁴⁰Clínica Médica C, Hospital de Clínicas, UDELAR, Montevideo, Uruguay, ⁴¹Unidad de Enfermedades Autoinmunes Sistémicas de Médica Uruguay Corporación de Asistencia Médica (MUCAM); Unidad de Enfermedades Autoinmunes Sistémicas del Hospital de Clínicas, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay, ⁴²University of Alabama at Birmingham, Birmingham, AL, ⁴³Global Commercial Strategic Organisation, Johnson and Johnson, Horsham, PA, ⁴⁴Janssen R&D, Spring House, PA, ⁴⁵Medical Affairs, Jan-Cil Argentina, Buenos Aires, Argentina, ⁴⁶Grupo Oroño. Centro Regional de Enfermedades Autoinmunes y Reumaticas (GO-CREAR), Rosario, Argentina
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by multiple and heterogeneous clinical manifestations that may negatively affect these patients’ quality of life…
Abstract Number: 1295 • ACR Convergence 2021
Belimumab Reduces Severe Flares in Systemic Lupus Erythematosus Across Multiple Patient Subgroups: Results of a Large Integrated Analysis
Michelle Petri¹, Norma Lynn Fox², Mathew Gibb³, Tania Gonzalez-Rivera², Anne Hammer², Holly Quasny⁴, Ronald van Vollenhoven⁵ and David Roth², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²GlaxoSmithKline, Collegeville, PA, ³Veramed Ltd., Twickenham, United Kingdom, ⁴GlaxoSmithKline, Research Triangle Park, NC, ⁵Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands
Background/Purpose: Belimumab (BEL) is a disease-modifying systemic lupus erythematosus (SLE) treatment that inhibits B-lymphocyte stimulator. BEL has demonstrated a consistent efficacy profile across 4 pivotal…
Abstract Number: 1446 • ACR Convergence 2021
Trauma Is Associated with Flares in Systemic Lupus Erythematosus (SLE)
Patricia Katz¹, Kimberly DeQuattro¹, Sarah Patterson², Laura Trupin³, Kamil Barbour⁴, Stephanie Rush¹, Cristina Lanata⁵, Jinoos Yazdany¹ and Maria Dall'Era⁶, ¹University of California San Francisco, San Francisco, CA, ²University of California San Francisco, Pacifica, CA, ³UC San Francisco, San Francisco, CA, ⁴Centers for Disease Control, Atlanta, GA, ⁵University of California San Francisco, Moss Beach, CA, ⁶University of California San Francisco, Corte Madera, CA
Background/Purpose: Daily psychological stress and trauma exposure with or without symptoms of post-traumatic stress disorder have been linked to an increased risk of SLE onset.1,…
Abstract Number: 1489 • ACR Convergence 2021
Identification of Mitochondrial Antigens Targeted by Autoantibodies in Systemic Lupus Erythematosus (SLE)
Yann BECKER¹, Jean-Philippe Gagné², Anne-Sophie Julien³, Tania Lévesque¹, Nadine Gougeard⁴, Vicente Rubio⁴, François-Michel Boisvert⁵, Dominique Jean⁶, Guy Poirier², Paul R Fortin⁷ and Éric Boilard¹, ¹Centre de Recherche ARThrite, Université Laval, Québec City, QC, Canada, ²Centre de Recherche du Centre Hospitalier Universitaire de Québec - Université Laval, Québec City, QC, Canada, ³Département de mathématiques et statistique, Université Laval, Québec, QC, Canada, ⁴Structural Enzymopathology Unit, Instituto de Biomedicina de Valencia, Consejo Superior de Investigaciones Científicas, Valencia, Spain, ⁵Department of Anatomy and Cell Biology, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁶Department of Anatomy and Cell Biology, Université de Sherbrooke, Sherbrooke, Canada, ⁷CHU de Quebec - Universite Laval, Québec City, QC, Canada
Background/Purpose: Mitochondria are organelles that possess several bacterial features such as a double-stranded genome with hypomethylated CpG islets, formylated proteins, and a double membrane composed…
Abstract Number: 1526 • ACR Convergence 2021
Development of Antinuclear Antibodies and Systemic Lupus Erythematosus in Patients on Tumor Necrosis Factor α Inhibitor Therapy
Chathura Wijewardena¹, Paramarajan Pirinavan¹, Sandy Nasr¹ and Andras Perl², ¹SUNY Upstate Medical University, Syracuse, NY, ²State University of New York, Syracuse, NY
Background/Purpose: Tumor necrosis factor α (TNF-α) inhibitor therapy has been widely used worldwide as a potent immunosuppressant for a variety of rheumatological diseases. Induction of…
Abstract Number: 1723 • ACR Convergence 2021
Factors Associated with Postpartum Flare in Women with Lupus
Anitha Ramu¹, Maedeh Veyseh¹, Brianna Lally², Shudan Wang³ and Anna Broder⁴, ¹Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, ⁴Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY
Background/Purpose: Several prior studies have assessed disease activity in the setting of pregnancy and have shown that certain factors such as thrombocytopenia, systemic lupus erythematosus…
Abstract Number: 1747 • ACR Convergence 2021
BIIB059 Demonstrates Improvement in Joint Manifestations in Participants with Systemic Lupus Erythematosus in Part a of a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Ronald van Vollenhoven¹, Richard Furie², Kenneth Kalunian³, Maria Dall'Era⁴, Victoria Werth⁵, Xiaobi Huang⁶, Hua Carroll⁶, Cristina Musselli⁶, Catherine Barbey⁷ and Nathalie Franchimont⁶, ¹Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ²Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ³UC San Diego, La Jolla, CA, ⁴University of California San Francisco, Corte Madera, CA, ⁵Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁶Biogen, Cambridge, MA, ⁷Biogen, Baar, Switzerland
Background/Purpose: Joint involvement, a frequent manifestation of SLE, can be assessed using global lupus disease activity indices (SLEDAI-2K, BILAG-2004) and/or by assessing joint tenderness and…
Abstract Number: 1766 • ACR Convergence 2021
Itolizumab-induced Modulation of Cell Surface CD6 Is a Pharmacodynamic Marker of Drug Activity in SLE Patients
Dalena Chu¹, Leslie Chinn², Jeanette Ampudia¹, Krishna Polu¹, Joel Rothman¹, Maple Fung³, Dolca Thomas⁴, Chaim Putterman⁵, Cherie Ng¹ and Stephen Connelly¹, ¹Equillium, Inc., La Jolla, CA, ²Equillium, Inc., South San Francisco, CA, ³Equillium, Inc., San Diego, CA, ⁴Equillium, Inc., Brooklyn, NY, ⁵Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Itolizumab (ITO) is a novel first-in-class monoclonal antibody (IgG1-k) specific for CD6, a co-stimulatory receptor that is highly expressed on T cells that plays…
Abstract Number: 1937 • ACR Convergence 2021
IL-16 Is Linked to Lupus Nephritis Activity
Andrea Fava¹, Deepak Rao², Chandra Mohan³, Ting Zhang³, Avi Rosenberg¹, Paride Fenaroli⁴, H. Michael Belmont⁵, Peter Izmirly⁶, Robert Clancy⁷, Jose Monroy-Trujillo¹, Derek Fine¹, Arnon Arazi⁸, Celine Berthier⁹, Anne Davidson¹⁰, Judith James¹¹, Betty Diamond¹², Nir Hacohen¹³, David Wofsy¹⁴, Soumya Raychaudhuri², Accelerating Medicines Partership (AMP) RA/SLE Network¹⁵, Jill Buyon⁵, Michelle Petri¹⁶ and The Accelerating Medicines Partnership in RA/SLE¹⁷, ¹Johns Hopkins University, Baltimore, MD, ²Brigham and Women's Hospital, Boston, MA, ³University of Houston, Houston, TX, ⁴Universita` degli Studi di Parma, Parma, Italy, ⁵NYU School of Medicine, New York, NY, ⁶New York University School of Medicine, New York, NY, ⁷NYU Grossman School of Medicine, New York, NY, ⁸Feinstein Institutes for Medical Research, Melrose, MA, ⁹University of Michigan, Ann Arbor, MI, ¹⁰Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, ¹¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²Northwell Health, Manhasset, NY, ¹³Broad Institute, Cambridge, MA, ¹⁴University of California San Francisco, San Francisco, CA, ¹⁵Brigham and Women's Hospital, Everett, MA, ¹⁶Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁷Multiple Institutions, Multiple
Background/Purpose: There is a pressing need to identify novel therapeutic targets in lupus nephritis. Multiomic approaches hold great potential for discovery. We integrated urine proteomics…
Abstract Number: 0083 • ACR Convergence 2021
Cardiac Valve Surgery Outcomes in the Antiphospholipid Syndrome
Tali Eviatar¹, Stanley Niznik², Nancy Agmon-Levin² and Daphna Paran³, ¹Tel Aviv Sourasky Medical Center, Givataim, Israel, ²Sheba Medical Center, Ramat Gan, Israel, ³Tel Aviv Sourasky Medical Center-Ichilov Hospital, Even Yehuda, Israel
Background/Purpose: Cardiac valve involvement in the APS is prevalent, necessitating valve surgery in about 5% of the patients. Data regarding valve surgery outcomes in APS…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].